Curated News
By: NewsRamp Editorial Staff
January 06, 2026

BioCorRx Appoints Louis Lucido as Board Chair in Leadership Transition

Discuss on Substack View History of this news story on GitHub
Original Source

TLDR

  • BioCorRx appoints experienced Louis Lucido as Board Chair, ensuring leadership continuity that could strengthen governance and strategic execution for competitive advantage.
  • BioCorRx's planned leadership transition involves Louis Lucido becoming Board Chair while Kent Emry remains as independent director, maintaining governance continuity through established processes.
  • BioCorRx's leadership continuity supports its mission to develop innovative treatments for substance abuse and obesity, potentially improving lives and public health outcomes.
  • BioCorRx's new Board Chair Louis Lucido brings extensive experience while the company develops implantable naltrexone pellets and FDA-approved opioid withdrawal medication.

Impact - Why it Matters

This leadership transition at BioCorRx matters because the company is at the forefront of addressing some of today's most pressing public health crises: addiction and obesity. With substance use disorders and obesity affecting millions globally—over 16.6 million have used methamphetamine, and an estimated 1 billion people are obese—effective treatments are urgently needed. BioCorRx's programs, like Beat Addiction Recovery and UnCraveRx®, offer innovative, integrated approaches that combine medication with behavioral support, potentially improving outcomes for patients. The appointment of Louis Lucido, with his extensive experience, could enhance the company's strategic direction, accelerating the development and availability of treatments such as LUCEMYRA® for opioid withdrawal and BICX104 for addiction. This impacts readers by highlighting advancements in healthcare that may offer new hope for individuals and families struggling with these conditions, while also underscoring the importance of corporate governance in driving medical innovation.

Summary

BioCorRx Inc. (OTCQB: BICX), a developer of innovative treatment programs for substance abuse and related disorders, has announced a significant leadership transition with Louis Lucido appointed as Chair of the Board of Directors, effective January 1, 2026. This planned change sees Lucido succeed Kent Emry, who has served on the board since 2013 and will continue as an independent director, ensuring governance continuity. Lucido, who joined the board in 2019 and has served as President since 2024, brings extensive board leadership experience from other organizations, positioning him to guide BioCorRx through its strategic objectives. CEO Lourdes Felix praised Emry's dedicated service since 2013 and highlighted Lucido's deep understanding of the company and leadership capabilities.

The company's core offerings include the Beat Addiction Recovery program, which combines proprietary Cognitive Behavioral Therapy (CBT) modules with peer support via mobile app and physician-prescribed medication, and the UnCraveRx® Weight Loss Program, a medication-assisted program with access to wellness specialists. For more information on UnCraveRx®, visit www.uncraverx.com. Through its subsidiary BioCorRx Pharmaceuticals Inc., the company commercializes LUCEMYRA® (lofexidine), an FDA-approved medication for mitigating opioid withdrawal symptoms in adults, and develops BICX104, an investigational implantable naltrexone pellet program. For details on BICX and its pipeline, visit www.BioCorRx.com. Research on BICX104 is supported by the National Institute On Drug Abuse under Award Number U01DA059994, though the content does not necessarily represent official NIH views.

BioCorRx addresses critical public health challenges, including methamphetamine use disorder (MUD), opioid use disorder (OUD), and obesity. Research has shown that methamphetamine is a highly addictive stimulant with severe side effects, and the 2022 National Survey on Drug Use and Health reported over 16.6 million lifetime users. OUD is a chronic disorder with serious consequences, while obesity affects an estimated 1 billion people globally, with the World Health Organization noting one in eight people live with obesity and stressing the need for new interventions. LUCEMYRA®, an oral tablet that reduces norepinephrine release to suppress opioid withdrawal, is indicated for adults and requires careful monitoring for side effects like low blood pressure and slow heart rate. For safety reporting, contact BioCorRx Pharmaceuticals Inc. at 1-833-LUCEMYRA or visit www.fda.gov/medwatch. The original release can be viewed on www.newmediawire.com.

Source Statement

This curated news summary relied on content disributed by NewMediaWire. Read the original source here, BioCorRx Appoints Louis Lucido as Board Chair in Leadership Transition

blockchain registration record for this content.